Advertisement

Intensive Care Medicine

, Volume 38, Issue 5, pp 811–819 | Cite as

Classification of sepsis, severe sepsis and septic shock: the impact of minor variations in data capture and definition of SIRS criteria

  • Peter M. C. Klein Klouwenberg
  • David S. Y. Ong
  • Marc J. M. Bonten
  • Olaf L. Cremer
Original

Abstract

Purpose

To quantify the effects of minor variations in the definition and measurement of systemic inflammatory response syndrome (SIRS) criteria and organ failure on the observed incidences of sepsis, severe sepsis and septic shock.

Methods

We conducted a prospective, observational study in a tertiary intensive care unit in The Netherlands between January 2009 and October 2010. A total of 1,072 consecutive adults were included. We determined the upper and lower limits of the measured incidence of sepsis by evaluating the influence of the use of an automated versus a manual method of data collection, and variations in the number of SIRS criteria, concurrency of SIRS criteria, and duration of abnormal values required to make a particular diagnosis.

Results

The measured incidence of SIRS varied from 49 % (most restrictive setting) to 99 % (most liberal setting). Subsequently, the incidences of sepsis, severe sepsis and septic shock ranged from 22 to 31 %, from 6 to 27 % and from 4 to 9 % for the most restrictive versus the most liberal measurement settings, respectively. In non-infected patients, 39–98 % of patients had SIRS, whereas still 17–6 % of patients without SIRS had an infection.

Conclusions

The apparent incidence of sepsis heavily depends on minor variations in the definition of SIRS and mode of data recording. As a consequence, the current consensus criteria do not ensure uniform recruitment of patients into sepsis trials.

Keywords

Systemic inflammatory response syndrome Sepsis Intensive care unit Clinical trial Epidemiology Diagnosis 

Notes

Acknowledgments

This research was performed within the framework of CTMM, the Center for Translational Molecular Medicine (http://www.ctmm.nl), project MARS (grant 04I-201). MB has received research funding from the Netherlands Organization of Scientific Research (NWO Vici 918.76.611).

References

  1. 1.
    Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101:1644–1655PubMedCrossRefGoogle Scholar
  2. 2.
    Sprung CL, Sakr Y, Vincent JL, Le Gall JR, Reinhart K, Ranieri VM, Gerlach H, Fielden J, Groba CB, Payen D (2006) An evaluation of systemic inflammatory response syndrome signs in the sepsis occurrence in acutely ill patients (SOAP) study. Intensive Care Med 32:421–427PubMedCrossRefGoogle Scholar
  3. 3.
    Vincent JL (1997) Dear SIRS, I’m sorry to say that I don’t like you. Crit Care Med 25:372–374PubMedCrossRefGoogle Scholar
  4. 4.
    Pittet D, Rangel-Frausto S, Li N, Tarara D, Costigan M, Rempe L, Jebson P, Wenzel RP (1995) Systemic inflammatory response syndrome, sepsis, severe sepsis and septic shock: incidence, morbidities and outcomes in surgical ICU patients. Intensive Care Med 21:302–309PubMedCrossRefGoogle Scholar
  5. 5.
    Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 31:1250–1256PubMedCrossRefGoogle Scholar
  6. 6.
    East TD (1992) Computers in the ICU: panacea or plague? Respir Care 37:170–180PubMedGoogle Scholar
  7. 7.
    Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709PubMedCrossRefGoogle Scholar
  8. 8.
    Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM (2001) Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286:1869–1878PubMedCrossRefGoogle Scholar
  9. 9.
    Arts D, de Keizer N, Scheffer GJ, de Jonge E (2002) Quality of data collected for severity of illness scores in the Dutch national intensive care evaluation (NICE) registry. Intensive Care Med 28:656–659PubMedCrossRefGoogle Scholar
  10. 10.
    Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM (2004) Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 32:858–873PubMedCrossRefGoogle Scholar
  11. 11.
    Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, Light B, Spapen H, Stone J, Seibert A, Peckelsen C, De Deyne C, Postier R, Pettila V, Artigas A, Percell SR, Shu V, Zwingelstein C, Tobias J, Poole L, Stolzenbach JC, Creasey AA (2003) Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290:238–247PubMedCrossRefGoogle Scholar
  12. 12.
    Annane D, Cariou A, Maxime V, Azoulay E, D’Honneur G, Timsit JF, Cohen Y, Wolf M, Fartoukh M, Adrie C, Santre C, Bollaert PE, Mathonet A, Amathieu R, Tabah A, Clec’h C, Mayaud J, Lejeune J, Chevret S (2010) Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial. JAMA 303:341–348PubMedCrossRefGoogle Scholar
  13. 13.
    Peake SL, Bailey M, Bellomo R, Cameron PA, Cross A, Delaney A, Finfer S, Higgins A, Jones DA, Myburgh JA, Syres GA, Webb SA, Williams P (2009) Australasian resuscitation of sepsis evaluation (ARISE): a multi-centre, prospective, inception cohort study. Resuscitation 80:811–818PubMedCrossRefGoogle Scholar
  14. 14.
    Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S (1998) Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on “sepsis-related problems” of the European Society of Intensive Care Medicine. Crit Care Med 26:1793–1800PubMedCrossRefGoogle Scholar
  15. 15.
    Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ (1995) Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med 23:1638–1652PubMedCrossRefGoogle Scholar
  16. 16.
    Le Gall JR, Klar J, Lemeshow S, Saulnier F, Alberti C, Artigas A, Teres D (1996) The logistic organ dysfunction system. A new way to assess organ dysfunction in the intensive care unit. ICU Scoring Group. JAMA 276:802–810PubMedCrossRefGoogle Scholar
  17. 17.
    Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G (2003) 2001 SCCM/ESICM/ACCP/ATS/sis international sepsis definitions conference. Intensive Care Med 29:530–538PubMedGoogle Scholar
  18. 18.
    Zimmerman JE, Kramer AA, McNair DS, Malila FM (2006) Acute physiology and chronic health evaluation (APACHE) IV: hospital mortality assessment for today’s critically ill patients. Crit Care Med 34:1297–1310PubMedCrossRefGoogle Scholar
  19. 19.
    Iba T, Kidokoro A (2004) What can we learn from the three megatrials using anticoagulants in severe sepsis? Shock 22:508–512PubMedCrossRefGoogle Scholar
  20. 20.
    LaRosa SP, Opal S (2004) Clinical trials of novel anticoagulants for severe sepsis: A tale of three molecules. Adv Sepsis 4:17–23Google Scholar
  21. 21.
    Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29:1303–1310PubMedCrossRefGoogle Scholar
  22. 22.
    Blanco J, Muriel-Bombin A, Sagredo V, Taboada F, Gandia F, Tamayo L, Collado J, Garcia-Labattut A, Carriedo D, Valledor M, De Frutos M, Lopez MJ, Caballero A, Guerra J, Alvarez B, Mayo A, Villar J (2008) Incidence, organ dysfunction and mortality in severe sepsis: a Spanish multicentre study. Crit Care 12:R158PubMedGoogle Scholar
  23. 23.
    Alberti C, Brun-Buisson C, Burchardi H, Martin C, Goodman S, Artigas A, Sicignano A, Palazzo M, Moreno R, Boulme R, Lepage E, Le Gall R (2002) Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med 28:108–121PubMedCrossRefGoogle Scholar
  24. 24.
    Brun-Buisson C, Meshaka P, Pinton P, Vallet B (2004) EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med 30:580–588PubMedCrossRefGoogle Scholar
  25. 25.
    Martin GS, Mannino DM, Eaton S, Moss M (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348:1546–1554PubMedCrossRefGoogle Scholar
  26. 26.
    Lever A, Mackenzie I (2007) Sepsis: definition, epidemiology, and diagnosis. BMJ 335:879–883PubMedCrossRefGoogle Scholar
  27. 27.
    Czura CJ (2011) “Merinoff symposium 2010: sepsis”—speaking with one voice. Mol Med 17:2–3PubMedCrossRefGoogle Scholar
  28. 28.
    Marshall JC (2006) Biomarkers of sepsis. Curr Infect Dis Rep 8:351–357PubMedCrossRefGoogle Scholar
  29. 29.
    Khor CC, Vannberg FO, Chapman SJ, Guo H, Wong SH, Walley AJ, Vukcevic D, Rautanen A, Mills TC, Chang KC, Kam KM, Crampin AC, Ngwira B, Leung CC, Tam CM, Chan CY, Sung JJ, Yew WW, Toh KY, Tay SK, Kwiatkowski D, Lienhardt C, Hien TT, Day NP, Peshu N, Marsh K, Maitland K, Scott JA, Williams TN, Berkley JA, Floyd S, Tang NL, Fine PE, Goh DL, Hill AV (2010) CISH and susceptibility to infectious diseases. N Engl J Med 362:2092–2101PubMedCrossRefGoogle Scholar
  30. 30.
    Chung TP, Laramie JM, Meyer DJ, Downey T, Tam LH, Ding H, Buchman TG, Karl I, Stormo GD, Hotchkiss RS, Cobb JP (2006) Molecular diagnostics in sepsis: from bedside to bench. J Am Coll Surg 203:585–598PubMedCrossRefGoogle Scholar
  31. 31.
    Bloos F, Hinder F, Becker K, Sachse S, Dessap AM, Straube E, Cattoir V, Brun-Buisson C, Reinhart K, Peters G, Bauer M (2010) A multicenter trial to compare blood culture with polymerase chain reaction in severe human sepsis. Intensive Care Med 36:241–247PubMedCrossRefGoogle Scholar
  32. 32.
    Tang BM, Eslick GD, Craig JC, McLean AS (2007) Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 7:210–217PubMedCrossRefGoogle Scholar
  33. 33.
    Marshall JC, Reinhart K (2009) Biomarkers of sepsis. Crit Care Med 37:2290–2298PubMedCrossRefGoogle Scholar
  34. 34.
    Tang BM, McLean AS, Dawes IW, Huang SJ, Lin RC (2009) Gene-expression profiling of peripheral blood mononuclear cells in sepsis. Crit Care Med 37:882–888PubMedCrossRefGoogle Scholar
  35. 35.
    Annane D, Bellissant E, Cavaillon JM (2005) Septic shock. Lancet 365:63–78PubMedCrossRefGoogle Scholar
  36. 36.
    Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG (1996) The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22:707–710PubMedCrossRefGoogle Scholar

Copyright information

© Copyright jointly held by Springer and ESICM 2012

Authors and Affiliations

  • Peter M. C. Klein Klouwenberg
    • 1
    • 2
  • David S. Y. Ong
    • 1
    • 2
  • Marc J. M. Bonten
    • 2
    • 3
  • Olaf L. Cremer
    • 1
  1. 1.Department of Intensive CareUniversity Medical Center UtrechtUtrechtThe Netherlands
  2. 2.Julius Center for Health Sciences and Primary CareUniversity Medical Center UtrechtUtrechtThe Netherlands
  3. 3.Department of Medical MicrobiologyUniversity Medical Center UtrechtUtrechtThe Netherlands

Personalised recommendations